Your browser doesn't support javascript.
Axillary adenopathy detected on breast MRI following COVID-19 vaccination: outcomes and follow-up recommendations.
Nguyen, Derek L; Chen, Xindi; Kwak, Lily; Oluyemi, Eniola T; Mullen, Lisa A; Ambinder, Emily B.
  • Nguyen DL; Johns Hopkins Medicine, 601 North Caroline St, Baltimore, MD 21287, United States of America. Electronic address: dnguye80@jhmi.edu.
  • Chen X; Johns Hopkins Medicine, 601 North Caroline St, Baltimore, MD 21287, United States of America. Electronic address: xchen220@jhmi.edu.
  • Kwak L; Johns Hopkins Medicine, 601 North Caroline St, Baltimore, MD 21287, United States of America. Electronic address: lkwak@jhmi.edu.
  • Oluyemi ET; Johns Hopkins Medicine, 601 North Caroline St, Baltimore, MD 21287, United States of America. Electronic address: eobadin1@jhmi.edu.
  • Mullen LA; Johns Hopkins Medicine, 601 North Caroline St, Baltimore, MD 21287, United States of America. Electronic address: lmullen1@jhmi.edu.
  • Ambinder EB; Johns Hopkins Medicine, 601 North Caroline St, Baltimore, MD 21287, United States of America. Electronic address: emcinto8@jhmi.edu.
Clin Imaging ; 93: 1-3, 2023 Jan.
Article in English | MEDLINE | ID: covidwho-2061007
ABSTRACT
This retrospective study presents 110 patients with suspected COVID-19 vaccine-related axillary adenopathy on breast MRI. Our study aimed to assess the outcomes of axillary adenopathy detected on breast MRI performed within one year after COVID-19 vaccination. The median time between the COVID-19 vaccine and breast MRI was shorter in patients with detected adenopathy compared to patients without detected adenopathy (6 weeks [2-17] versus 15 [7-24] weeks, p < 0.001). Unilateral axillary adenopathy detected on breast MRI had a low malignancy rate (3.3%), and no cases of malignant axillary adenopathy were diagnosed without a known breast cancer in the ipsilateral breast. Our findings suggest that unilateral axillary adenopathy identified on breast MRI ipsilateral to a recent COVID-19 vaccination can be considered benign in the absence of a suspicious breast finding or known breast cancer. Regardless of vaccine status and timing, unilateral axillary adenopathy detected on MRI evaluation with a known malignancy or suspicious breast finding should be considered suspicious. This will avoid unnecessary scheduling constraints, patient anxiety, and cost, without delaying diagnosis of metastatic breast cancer.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Breast Neoplasms / Lymphadenopathy / COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Female / Humans Language: English Journal: Clin Imaging Journal subject: Diagnostic Imaging Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Breast Neoplasms / Lymphadenopathy / COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Female / Humans Language: English Journal: Clin Imaging Journal subject: Diagnostic Imaging Year: 2023 Document Type: Article